Cargando…
Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply
Autores principales: | Horby, Peter, Staplin, Natalie, Haynes, Richard, Landray, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298006/ https://www.ncbi.nlm.nih.gov/pubmed/34303433 http://dx.doi.org/10.1016/S0140-6736(21)01422-7 |
Ejemplares similares
-
Allocated but not treated: the silent 16% – Authors' reply
por: Horby, Peter, et al.
Publicado: (2022) -
Tocilizumab in COVID-19 therapy: who benefits, and how?
por: Yang, Chengliang, et al.
Publicado: (2021) -
Tocilizumab in COVID-19 therapy: who benefits, and how?
por: Neumann, Avidan U, et al.
Publicado: (2021) -
Tocilizumab for severe COVID-19 pneumonia – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020) -
Tocilizumab in COVID-19: finding the optimal route and dose – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)